These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21234628)

  • 1. The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) α-308 G/G promoter polymorphism.
    Soto L; Sabugo F; Catalan D; Wurmann P; Cermenatti T; Gatica H; Aravena O; Salazar L; Aguillón JC; Cuchacovich M
    Clin Rheumatol; 2011 Mar; 30(3):391-5. PubMed ID: 21234628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
    Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
    J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis.
    Cuchacovich M; Soto L; Edwardes M; Gutierrez M; Llanos C; Pacheco D; Sabugo F; Alamo M; Fuentealba C; Villanueva L; Gatica H; Schiattino I; Salazaro L; Catalan D; Valenzuela O; Salazar-Onfray F; Aguillón JC
    Scand J Rheumatol; 2006; 35(6):435-40. PubMed ID: 17343250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis.
    Bos WH; Bartelds GM; Vis M; van der Horst AR; Wolbink GJ; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Lems WF; Nurmohamed MT; Aarden L; Hamann D
    Ann Rheum Dis; 2009 Apr; 68(4):558-63. PubMed ID: 18445623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement system and rheumatoid arthritis: relationships with autoantibodies, serological, clinical features, and anti-TNF treatment.
    Di Muzio G; Perricone C; Ballanti E; Kroegler B; Greco E; Novelli L; Conigliaro P; Cipriani P; Giacomelli R; Perricone R
    Int J Immunopathol Pharmacol; 2011; 24(2):357-66. PubMed ID: 21658310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study.
    Klaasen R; Cantaert T; Wijbrandts CA; Teitsma C; Gerlag DM; Out TA; de Nooijer MJ; Baeten D; Tak PP
    Rheumatology (Oxford); 2011 Aug; 50(8):1487-93. PubMed ID: 21454308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-alpha treatment response in rheumatoid arthritis.
    Dejaco C; Duftner C; Klotz W; Schirmer M; Herold M
    Rheumatol Int; 2010 Feb; 30(4):451-4. PubMed ID: 19506882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
    Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
    Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
    Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
    Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers.
    Fabris M; Quartuccio L; Vital E; Pontarini E; Salvin S; Fabro C; Zabotti A; Benucci M; Manfredi M; Ravagnani V; Biasi D; Atzeni F; Sarzi-Puttini P; Morassi P; Fischetti F; Bazzicchi L; Saracco M; Pellerito R; Cimmino M; Carraro V; Semeraro A; Schiavon F; Caporali R; Bortolotti R; Govoni M; Fogolari F; Tonutti E; Bombardieri S; Emery P; De Vita S
    Arthritis Rheum; 2013 Jan; 65(1):88-97. PubMed ID: 23001900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.
    Shu J; Bykerk VP; Boire G; Haraoui B; Hitchon C; Thorne JC; Tin D; Keystone EC; Pope JE;
    J Rheumatol; 2015 Nov; 42(11):2023-8. PubMed ID: 26329342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.
    Bobbio-Pallavicini F; Caporali R; Alpini C; Avalle S; Epis OM; Klersy C; Montecucco C
    Ann Rheum Dis; 2007 Mar; 66(3):302-7. PubMed ID: 17079248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
    Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
    Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis.
    Cuchacovich M; Catalan D; Wainstein E; Gatica H; Soto L; Aravena O; Pesce B; Sabugo F; Aguillón JC
    Clin Exp Rheumatol; 2008; 26(6):1067-73. PubMed ID: 19210871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents.
    Halvorsen EH; Haavardsholm EA; Pollmann S; Boonen A; van der Heijde D; Kvien TK; Molberg Ø
    Ann Rheum Dis; 2009 Feb; 68(2):249-52. PubMed ID: 18723564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study.
    Suarez-Gestal M; Perez-Pampin E; Calaza M; Gomez-Reino JJ; Gonzalez A
    Arthritis Res Ther; 2010; 12(2):R72. PubMed ID: 20423481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.
    Potter C; Hyrich KL; Tracey A; Lunt M; Plant D; Symmons DP; Thomson W; Worthington J; Emery P; Morgan AW; Wilson AG; Isaacs J; Barton A;
    Ann Rheum Dis; 2009 Jan; 68(1):69-74. PubMed ID: 18375541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
    Jamnitski A; Bartelds GM; Nurmohamed MT; van Schouwenburg PA; van Schaardenburg D; Stapel SO; Dijkmans BA; Aarden L; Wolbink GJ
    Ann Rheum Dis; 2011 Feb; 70(2):284-8. PubMed ID: 21068090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort.
    Mavragani CP; La DT; Stohl W; Crow MK
    Arthritis Rheum; 2010 Feb; 62(2):392-401. PubMed ID: 20112385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.